Unapproved Drug Sold Illegally for Weight Loss

Australians are acquiring the experimental weight-loss drug Retatrutide through illicit online channels. Suppliers deceptively label the product as "for research use only" while shipping it directly to consumers' homes, often with guidance from fitness influencers.

This peptide, still in phase 3 clinical trials by Eli Lilly, has not received regulatory approval anywhere worldwide. Pharmacologists express serious concerns, highlighting that the drug's safety and long-term effects remain unknown. The unregulated nature of these online sales means users inject potentially dangerous, non-pharmaceutical-grade substances.

Risks include severe side effects similar to approved GLP1 agonists, such as gastrointestinal issues, pancreatitis, and dangerous rapid weight loss. Furthermore, improperly folded peptides can trigger adverse immune responses, including anaphylaxis. The US Food and Drug Administration has also flagged similar illegal sales practices.

Authorities are attempting to remove unlawful advertisements, but enforcement remains challenging. The Therapeutic Goods Administration has requested thousands of removals, though Retatrutide is not a high-priority substance for customs. The global sale of such unverified drugs highlights a significant public health concern.